[Lysophospholipid mediators].
Makide
Kumiko
K
makide@mail.pharm.tohoku.ac.jp
Kano
Kuniyuki
K
Kitamura
Hajime
H
Arima
Naoaki
N
Aoki
Junken
J
D000818:Animals; D002468:Cell Physiological Phenomena; D015195:Drug Design; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents; D007249:Inflammation / Q000209:etiology; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008246:Lysophospholipids / Q000378:metabolism / Q000502:physiology*; D018377:Neurotransmitter Agents / Q000378:metabolism; D011409:Propylene Glycols / Q000494:pharmacology; D043562:Receptors, G-Protein-Coupled / Q000502:physiology; D013110:Sphingosine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology
D007166:Immunosuppressive Agents; D007328:Insulin; D008246:Lysophospholipids; D018377:Neurotransmitter Agents; D011409:Propylene Glycols; D043562:Receptors, G-Protein-Coupled; C008301:lysophosphatidylethanolamine; C026223:lysophosphatidylglycerol; C025449:lysophosphatidylinositol; C025059:lysophosphatidylserine; C060506:sphingosine 1-phosphate; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine; C032881:lysophosphatidic acid